ROS1 and non-small cell lung carcinoma: Among five brain metastases from NSCLC, two of them harbored a mutation/deletion in EGFR as detected by targeted sequencing (Fig EV2R); however, no molecular alterations in EGFR, ALK, and ROS1 were found in the other three patients using standard methodologies approved in clinical practice for these biomarkers (Fig EV2Q).